Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?

For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. I...

Full description

Saved in:
Bibliographic Details
Published in:Stem cell research & therapy 2017-10, Vol.8 (1), p.238-238, Article 238
Main Authors: Roura, Santiago, Gálvez-Montón, Carolina, Mirabel, Clémentine, Vives, Joaquim, Bayes-Genis, Antoni
Format: Article
Language:English
Subjects:
Adipose tissue
Adipose Tissue - cytology
Adipose Tissue - physiology
Adipose tissues
Analysis
Animals
Cardiac adipose tissue
Cardiac repair
Cell cycle
Cell Differentiation
Cell therapy
Cell- and Tissue-Based Therapy - methods
Clinical trials
Cord blood
Disease Models, Animal
Evidence-based medicine
Fetal Blood - cytology
Fetal Blood - physiology
Fetal Blood - transplantation
Good Manufacturing Practice
Heart attacks
Heart diseases
Heart failure
Heart Failure - pathology
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Laboratories
Mesenchymal Stem Cell Transplantation
Mesenchymal stem cells
Mesenchymal Stem Cells - cytology
Mesenchymal Stem Cells - physiology
Mesenchyme
Mice
Mortality
Myocardial infarction
Myocardial Infarction - pathology
Myocardial Infarction - physiopathology
Myocardial Infarction - therapy
Practice Guidelines as Topic
Rats
Review
Stem cells
Studies
Swine
Tissue engineering
Tissue Engineering - methods
Transplantation
Transplants & implants
Umbilical cord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.
ISSN:1757-6512
1757-6512
DOI:10.1186/s13287-017-0695-y